The herpes zoster subunit vaccine

Expert Opinion on Biological Therapy

Volumn 16, Issue 2, 2016, Pages 265-271

  Cunningham, Anthony L ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Herpes zoster; HZ su vaccine; Postherpetic neuralgia; Vaccine

Indexed keywords

AS 01B; CORTICOSTEROID; PHOSPHORYL LIPID A; PLACEBO; QS 21; SUBUNIT VACCINE; UNCLASSIFIED DRUG; VARICELLA ZOSTER SUBUNIT VACCINE; VARICELLA ZOSTER VACCINE; VIRUS GLYCOPROTEIN; IMMUNOLOGICAL ADJUVANT; LIVE VACCINE;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTIVIRAL ACTIVITY; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; DISEASE SEVERITY; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; GROUPS BY AGE; HERPES ZOSTER; HUMAN; IMMUNOCOMPETENCE; IMMUNOCOMPROMIZED PATIENT; IMMUNOGENICITY; INFECTION RISK; INJECTION SITE ERYTHEMA; INJECTION SITE REACTION; INJECTION SITE SWELLING; LATENT VIRUS INFECTION; NONHUMAN; OUTCOME ASSESSMENT; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROTECTION; RISK REDUCTION; T LYMPHOCYTE; VIRUS REPLICATION; ANIMAL; IMMUNOLOGY; NEURALGIA, POSTHERPETIC; VARICELLA ZOSTER VIRUS;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; HERPES ZOSTER; HERPES ZOSTER VACCINE; HERPESVIRUS 3, HUMAN; HUMANS; IMMUNOCOMPETENCE; NEURALGIA, POSTHERPETIC; VACCINES, ATTENUATED; VACCINES, SUBUNIT;

EID: 84957933049     PISSN: 14712598     EISSN: 17447682     Source Type: Journal    
DOI: 10.1517/14712598.2016.1134481     Document Type: Article

References (43)

1. Arvin AM. Humoral and cellular immunity to varicellazoster virus: an overview. J Infect Dis. 2008;197(Suppl 2): S58-60. DOI:10.1086/522123.
2. Steain M, Sutherland JP, Rodriguez M, et al. Analysis of T cell responses during active varicella zoster virus reactivation in human ganglia. J Virol. 2014;8(5):2704-2716.
3. Hope-Simpson RE. Postherpetic neuralgia. J R Coll Gen Pract. 1975;25:571-575.
4. Yawn BP, Saddier P, Wollan PC, et al. A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction. Mayo Clin Proc. 2007;82:1341-1349.
5. Macintyre R, Stein A, Harrison C, et al. Increasing trends of herpes zoster in Australia. PLoS One. 2015;10: e0125025. DOI:10.1371/journal.pone.0125025.
6. Cohen JI. Herpes zoster. N Engl J Med. 2013;369:1766-1767. DOI:10.1056/NEJMc1310369.
7. Gershon AA, Gershon MD, Breuer J, et al. Advances in the understanDing of the pathogenesis and epidemiology of herpes zoster. J Clin Virol. 2010;48(Suppl 1):S2-7. DOI:10.1016/S1386-6532(10)70002-0.
8. Johnson RW. Herpes zoster and postherpetic neuralgia. Expert Rev Vaccines. 2010;9:21-26. DOI:10.1586/erv.10.30.
9. Oxman MN, Levin MJ, Johnson GR, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med. 2005;352:2271-2284. DOI:10.1056/NEJMoa051016.
10. Chen N, Li Q, Yang J, et al. Antiviral treatment for preventing postherpetic neuralgia. Cochrane Database Syst Rev. 2014;2:CD006866.
11. Levin MJ, Smith JG, Kaufhold RM, et al. Decline in varicellazoster virus (VZV)-specific cell-mediated immunity with increasing age and boosting with a high-dose VZV vaccine. J Infect Dis. 2003;188:1336-1344. DOI:10.1086/379048.
12. Miller AE. Selective decline in cellular immune response to varicella-zoster in the elderly. Neurology. 1980;30:582-587.
13. Weinberg A, Levin MJ, Macgregor RR. Safety and immunogenicity of a live attenuated varicella vaccine in VZV-seropositive HIV-infected adults. Hum Vaccin. 2010;6:318-321.
14. Trannoy E, Berger R, Hollander G, et al. Vaccination of immunocompetent elderly subjects with a live attenuated Oka strain of varicella zoster virus: a randomized, controlled, dose-response trial. Vaccine. 2000;18:1700-1706.
15. Schmader KE, Levin MJ, Gnann JW Jr, et al Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50-59 years. Clin Infect Dis. 2012;54:922-928. DOI:10.1093/cid/cir970.
16. Harpaz R, Ortega-Sanchez IR, Seward JF, et al. Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2008;57:1-30. quiz CE2-4.
17. Clark TG, Cassidy-Hanley D. Recombinant subunit vaccines: potentials and constraints. Dev Biol (Basel). 2005;121:153-163.
18. Plotkin SA. Vaccines: past, present and future. Nat Med. 2005;11:S5-11. DOI:10.1038/nm1209.
19. Haumont M, Jacquet A, Massaer M, et al. Purification, characterization and immunogenicity of recombinant varicella-zoster virus glycoprotein gE secreted by Chinese hamster ovary cells. Virus Res. 1996;40:199-204.
20. Malavige GN, Jones L, Black AP, et al. Varicella zoster virus glycoprotein E-specific CD4+ T cells show evidence of recent activation and effector differentiation, consistent with frequent exposure to replicative cycle antigens in healthy immune donors. Clin Exp Immunol. 2008;152:522-531. DOI:10.1111/j.1365-2249.2008.03633.x.
21. Vafai A. Boosting immune response with a candidate varicella-zoster virus glycoprotein subunit vaccine. Vaccine. 1995;13:1336-1338.
22. Dendouga N, Fochesato M, Lockman L, et al. Cellmediated immune responses to a varicella-zoster virus glycoprotein E vaccine using both a TLR agonist and QS21 in mice. Vaccine. 2012;30:3126-3135. DOI:10.1016/j.vaccine.2012.01.088.
23. Garcon N, Van Mechelen M. Recent clinical experience with vaccines using MPL-and QS-21-containing adjuvant systems. Expert Rev Vaccines. 2011;10:471-486. DOI:10.1586/erv.11.29.
24. Vandepapeliere P, Horsmans Y, Moris P, et al. Vaccine adjuvant systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers. Vaccine. 2008;26:1375-1386. DOI:10.1016/j.vaccine.2007.12.038.
25. Chlibek R, Pauksens K, Rombo L, et al. Long-term immunogenicity and safety of an investigational herpes zoster subunit vaccine in older adults. Vaccine. 2015. DOI:10.1016/j.vaccine.2015.09.073.
26. Chlibek R, Smetana J, Pauksens K, et al. Safety and immunogenicity of three different formulations of an adjuvanted varicella-zoster virus subunit candidate vaccine in older adults: a phase II, randomized, controlled study. Vaccine. 2014;32:1745-1753. DOI:10.1016/j. vaccine.2014.01.019.
27. Leroux-Roels I, Leroux-Roels G, Clement F, et al. A phase 1/2 clinical trial evaluating safety and immunogenicity of a varicella zoster glycoprotein e subunit vaccine candidate in young and older adults. J Infect Dis. 2012;206:1280-1290. DOI:10.1093/infdis/jis497.
28. Lal H, Cunningham AL, Godeaux O, et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med. 2015;372:2087-2096. DOI:10.1056/NEJMoa1501184.
29. Oxman MN. Zoster vaccine: current status and future prospects. Clin Infect Dis. 2010;51:197-213. DOI:10.1086/653605.
30. Gilbert PB, Gabriel EE, Miao X, et al. Fold rise in antibody titers by measured by glycoprotein-based enzyme-linked immunosorbent assay is an excellent correlate of protection for a herpes zoster vaccine, demonstrated via the vaccine efficacy curve. J Infect Dis. 2014;210:1573-1581. DOI:10.1093/infdis/jiu279.
31. Gowrishankar K, Steain M, Cunningham AL, et al. Characterization of the host immune response in human Ganglia after herpes zoster. J Virol. 2010;84:8861-8870. DOI:10.1128/JVI.01020-10.
32. Dorrington MG, Bowdish DM. Immunosenescence and novel vaccination strategies for the elderly. Front Immunol. 2013;4:171. DOI:10.3389/fimmu.2013.00171.
33. Levin MJ. Immune senescence and vaccines to prevent herpes zoster in older persons. Curr Opin Immunol. 2012;24:494-500. DOI:10.1016/j. coi.2012.06.002.
34. Linton PJ, Dorshkind K. Age-related changes in lymphocyte development and function. Nat Immunol. 2004;5:133-139. DOI:10.1038/ni1033.
35. Didierlaurent AM, Collignon C, Bourguignon P, et al. Enhancement of adaptive immunity by the human vaccine adjuvant AS01 depends on activated dendritic cells. J Immunol. 2014;193:1920-1930. DOI:10.4049/jimmunol.1400948.
36. Chlibek R, Bayas JM, Collins H, et al. Safety and immunogenicity of an AS01-adjuvanted varicella-zoster virus subunit candidate vaccine against herpes zoster in adults ?50 years of age. J Infect Dis. 2013;208:1953-1961. DOI:10.1093/infdis/jit365.
37. Leroux-Roels I, Koutsoukos M, Clement F, et al. Strong and persistent CD4+ T-cell response in healthy adults immunized with a candidate HIV-1 vaccine containing gp120, Nef and Tat antigens formulated in three Adjuvant Systems. Vaccine. 2010;28:7016-7024. DOI:10.1016/j.vaccine.2010.08.035.
38. Tavares Da Silva F, De Keyser F, Lambert PH, et al. Optimal approaches to data collection and analysis of potential immune mediated disorders in clinical trials of new vaccines. Vaccine. 2013;31:1870-1876. DOI:10.1016/j.vaccine.2013.01.042.
39. Stadtmauer EA, Sullivan KM, Marty FM, et al. A phase 1/2 study of an adjuvanted varicella-zoster virus subunit vaccine in autologous hematopoietic cell transplant recipients. Blood. 2014;124:2921-2929. DOI:10.1182/blood-2014-04-573048.
40. Berkowitz EM, Moyle G, Stellbrink HJ, et al. Safety and immunogenicity of an adjuvanted herpes zoster subunit candidate vaccine in HIV-infected adults: a phase 1/2a randomized, placebo-controlled study. J Infect Dis. 2015;211:1279-1287. DOI:10.1093/infdis/jiu606.
41. Zhang J, Xie F, Delzell E, et al. Association between vaccination for herpes zoster and risk of herpes zoster infection among older patients with selected immunemediated diseases. JAMA. 2012;308:43-49. DOI:10.1001/jama.2012.7304.
42. Tseng HF, Tartof S, Harpaz R, et al. Vaccination against zoster remains effective in older adults who later undergo chemotherapy. Clin Infect Dis. 2014;59:913-919. DOI:10.1093/cid/ciu498.
43. Hata A, Asanuma H, Rinki M, et al. Use of an inactivated varicella vaccine in recipients of hematopoietic-cell transplants. N Engl J Med. 2002;347:26-34. DOI:10.1056/NEJMoa013441.